Zoetis(US:ZTS) Seeking Alpha·2026-01-16 17:30Core Viewpoint - Zoetis Inc. (ticker symbol ZTS) is currently rated as a Hold by both the Seeking Alpha Quant rating system and analysts, while Wall Street analysts have a Buy rating on the stock [2][3]. Company Overview - Zoetis has a market capitalization of $54.92 billion and operates within the healthcare sector, specifically in the pharmaceuticals industry [4]. Valuation Metrics - The company's valuation grade is a D-, with an Enterprise Value-to-EBITDA ratio of 14.65, compared to the sector average of 12.71. The PEG non-GAAP Forward ratio stands at 2.58, above the sector's 1.76, indicating potential overvaluation [4]. Growth Metrics - The growth grade is a D-, with year-over-year revenue growth at 2.68%, which is below the sector median of 6.38% and also below the company's five-year average of 8.06% [5]. Profitability Metrics - Zoetis has an A+ grade in profitability, with a net income margin of 28.21%, significantly higher than the sector average [5]. Momentum Metrics - The momentum grade is D+, with a one-year price performance decline of 25.07%, while the sector performance has been relatively flat [6]. Revisions Metrics - The revisions grade is D+, with three upward revisions and 12 downward revisions for earnings per share in the last three months, and one upward revision and 14 downward revisions for revenue in the same period [6]. Dividend Information - Zoetis pays a dividend yield of 1.70%, with a five-year growth rate of 20.11%. The safety grade for the dividend is A, and the consistency grade is B-, as the company has been paying dividends for 12 years [7].